These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 18454377)

  • 1. The treatment of choroidal neovascularisation with intravitreal injections of bevacizumab (Avastin).
    Valmaggia C; Niederberger H; Lang C; Kloos P; Haueter I
    Klin Monbl Augenheilkd; 2008 May; 225(5):380-4. PubMed ID: 18454377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
    Ehrlich R; Ciulla TA; Maturi R; Kheradiya NS; Hrisomalos N; Shulman S; Guess MG; Coyle E; Harris A
    Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.
    Ruiz-Moreno JM; Montero JA; Gomez-Ulla F; Ares S
    Br J Ophthalmol; 2009 Apr; 93(4):448-51. PubMed ID: 19091851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV; Steén B; Seregard S; Kvanta A
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of choroidal neovascularizations in age-related macular degeneration using either Avastin or Lucentis.
    Valmaggia C; Haueter I; Kloos P; Lang C; Niederberger H
    Klin Monbl Augenheilkd; 2009 Apr; 226(4):294-8. PubMed ID: 19384786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum.
    Finger RP; Charbel Issa P; Ladewig M; Holz FG; Scholl HP
    Br J Ophthalmol; 2008 Apr; 92(4):483-7. PubMed ID: 18369065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab for choroidal neovascularization related to inflammatory diseases.
    Kramer M; Axer-Siegel R; Jaouni T; Reich E; Hemo I; Priel E; Averbukh E; Ehrlich R; Chowers I; Weinberger D; Amer R
    Retina; 2010 Jun; 30(6):938-44. PubMed ID: 20168273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
    Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
    Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy.
    Parodi MB; Iacono P; Cascavilla M; Zucchiatti I; Kontadakis DS; Bandello F
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4358-61. PubMed ID: 20375343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
    Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks.
    Wiegand TW; Rogers AH; McCabe F; Reichel E; Duker JS
    Br J Ophthalmol; 2009 Jan; 93(1):47-51. PubMed ID: 18971238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM; Lai TY; Liu DT; Lam DS
    Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
    Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.